Effect of the microtransplantation of allogeneic hematopoietic stem cells as maintenance therapy for elderly patients with acute leukemia

Juliusson G, Antunovic P, Derolf A, et al: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 113:4179–4187. 2009. View Article : Google Scholar : PubMed/NCBI

Vey N: Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress? Interdiscip Top Gerontol. 38:73–84. 2013.PubMed/NCBI

Yanada M, Ohtake S, Miyawaki S, et al: Japan Adult Leukemia Study Group: The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. Cancer. 119:3326–3333. 2013. View Article : Google Scholar : PubMed/NCBI

Shimoni A, Kroger N, Zabelina T, et al: Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia. 19:7–12. 2005.PubMed/NCBI

Lazarevic V, Horstedt AS, Johansson B, et al: Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J. 4:e1882014. View Article : Google Scholar : PubMed/NCBI

Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 94:1086–1099. 1999.PubMed/NCBI

Leone G, Mele L, Pulsoni A, Equitani F and Pagano L: The incidence of secondary leukemias. Haematologica. 84:937–945. 1999.PubMed/NCBI

Ostgård LS, Kjeldsen E, Holm MS, et al: Reasons for treating secondary AML as de novo AML. Eur J Haematol. 85:217–226. 2010. View Article : Google Scholar : PubMed/NCBI

Guo M, Hu KX, Yu CL, et al: Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 117:936–941. 2011. View Article : Google Scholar : PubMed/NCBI

Guo M, Hu KX, Liu GX, et al: HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol. 30:4084–4090. 2012. View Article : Google Scholar : PubMed/NCBI

Chen YS, Kong XJ, Zhang XH and Yin XL: Treatment of acute mixed-cell leukemia with autologous hematopoietic SCT followed by allogeneic hematopoietic stem cell micro-transplantation. Bone Marrow Transplant. 49:984–985. 2014. View Article : Google Scholar : PubMed/NCBI

Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood. 107:3481–3485. 2006. View Article : Google Scholar : PubMed/NCBI

Al-Seraihy AS, Owaidah TM, Ayas M, El-Solh H, Al-Mahr M, Al-Ahmari A and Belgaumi AF: Clinical characteristics and outcome of children with biphenotypic acute leukemia. Haematologica. 94:1682–1690. 2009. View Article : Google Scholar : PubMed/NCBI

Miyawaki S, Sakamaki H, Ohtake S, et al: Japan Adult Leukemia Study Group AML 97 Study: A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer. 104:2726–2734. 2005. View Article : Google Scholar : PubMed/NCBI

Hengeveld M, Suciu S, Karrasch M, et al: Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Ann Hematol. 91:825–835. 2012. View Article : Google Scholar : PubMed/NCBI

Büchner T, Hiddemann W, Berdel WE, et al: German AML Cooperative Group: 6-Thioguanine, cytarabine and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 21:4496–4504. 2003.PubMed/NCBI

Ferrero D, Crisà E, Marmont F, et al: Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. Ann Hematol. 93:1391–1400. 2014. View Article : Google Scholar : PubMed/NCBI

Lö Wenberg B, Suciu S, Archimbaud E, et al: Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 16:872–881. 1998.PubMed/NCBI

Polák J, Hájková H, Maalaufová-Soukupová J, et al: Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression. Exp Ther Med. 3:129–133. 2012.PubMed/NCBI